Although various pharmacological and non-pharmacological interventions have been adopted to influence adiponectin levels, the clinical relevance of the elevated adiponectin level to the reduction of the endometrial cancer risk remains to be determined [49]. This evidence concerns the gene ADIPOQ and endometrial cancer.